Angle Reels In Positive Clinical Results In Ovarian Cancer Study
Liquid biopsy company Angle plc, has reported positive results for its first large-scale study in Europe and the US using its Parsortix system to detect ovarian cancer. The study evaluated 400 patients for the detection of ovarian cancer in women with a high-risk pelvic mass.
You may also be interested in...
Abbott and UK-based Angle plc announced they will collaborate on a breast cancer liquid biopsy study, assessing Angle's technology for harvesting circulating tumor cells in combination with Abbott's FDA-approved gene-based test for determining HER-2 status.
Liquid biopsies – carrying out diagnostic tests on liquid samples such as blood or urine rather than on tissue biopsy material – look set to revolutionize the management of cancer patients. This area has recently captured the interest of a growing number of diagnostic players, both big and small, and spawned the development of different approaches to liquid biopsy. This article marks out who's who in this increasingly busy landscape and the key technologies that are showing promise, and looks at the obstacles that companies are facing.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.